Back to search
FDAFDA · Food and drugs·Recall number D-0583-2026

Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Published June 17, 2026 · Recall initiated: June 4, 2026

Summary

FDA records drug Class II recall D-0583-2026, published June 17, 2026 and initiated June 4, 2026. Recalling firm: Breckenridge Pharmaceutical, Inc.; Status: Ongoing; Reported quantity: 359,676 bottles; Lot: Lot: a) 241074C, Exp. Date May 2027; 240317, 240318, 240315C, 240373C, 240370C, 240375C, 240413C, Exp. Date February 2027; 240316,Exp. Date January 2027; 232311, Exp. Date November 2026; b) 240978C, 241052C, Exp. Date April 2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Get an email if DULOXETINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DULOXETINE
Manufacturer
Breckenridge Pharmaceutical, Inc.
Distributor
Nationwide within the United States
Lot
Lot: a) 241074C, Exp. Date May 2027; 240317, 240318, 240315C, 240373C, 240370C, 240375C, 240413C, Exp. Date February 2027; 240316,Exp. Date January 2027; 232311, Exp. Date November 2026; b) 240978C, 241052C, Exp. Date April 2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. recalled?

Yes. FDA published recall D-0583-2026 on June 17, 2026. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DULOXETINE.